← Leaderboards
Sourav Ghosh
University Of Arizona
$5,263,749
Attributed
$12,164,469
Total exposure
6
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.3M · FY2010–25$5M$3.8M$2.5M$1.3M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,164,469 · 6
By mechanism
R01$6,800,328 · 3
R56$2,511,356 · 1
RF1$2,392,160 · 1
R21$460,625 · 1
Top collaborators
- Carla Rothlin16 shared
- Silvia C Finnemann3 shared
- Stephen M Strittmatter2 shared
- Le Zhang2 shared
- Hongyu Zhao2 shared
- Jaime Grutzendler1 shared
- Tamas L Horvath1 shared
Most similar at University Of Arizona
Same institution · by research overlap
- Gregory R J Thatcher$19,556,155
- Carol A. Barnes$55,681,144
- Maya Henry$7,481,935
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposCellsSignal TransductionComplementMolecularTumorGrowthTumor GrowthSignal PathwayMalignant NeoplasmsMouse ModelResistanceDefectPreventGeneticBaseGenesLeadMertk GenePathway InteractionsExcisionDiagnosisAblationPre-Clinical
Grant awards (25)
Inflammation in MERTK-dependent retinitis pigmentosa$663,495
R01 · FY2025 · EY
Inflammation in MERTK-dependent retinitis pigmentosa$663,495
R01 · FY2024 · EY
Naïve T cell archetypes and anti-tumor immunity$209,375
R21 · FY2024 · AI
Augmenting AXL and MERTK function to restrain cognitive decline and improve health span in mouse models of Alzheimer's Disease$2,392,160
RF1 · FY2023 · AG
Inflammation in MERTK-dependent retinitis pigmentosa$679,733
R01 · FY2023 · EY
Naïve T cell archetypes and anti-tumor immunity$251,250
R21 · FY2023 · AI
Sex-Specific Single Cell Expression Profiles, Genetic Risk and Drug Responsiveness in Alzheimer's Disease$1,255,677
R56 · FY2022 · AG
Sex-Specific Single Cell Expression Profiles, Genetic Risk and Drug Responsiveness in Alzheimer's Disease$1,255,679
R56 · FY2021 · AG
An innate immune checkpoint in cancer immunotherapy$458,186
R01 · FY2021 · CA
An innate immune checkpoint in cancer immunotherapy$415,512
R01 · FY2021 · CA
An innate immune checkpoint in cancer immunotherapy$527,107
R01 · FY2020 · CA
An innate immune checkpoint in cancer immunotherapy$444,441
R01 · FY2019 · CA
An innate immune checkpoint in cancer immunotherapy$176,697
R01 · FY2019 · CA
An innate immune checkpoint in cancer immunotherapy$468,186
R01 · FY2018 · CA
An innate immune checkpoint in cancer immunotherapy.$113,240
R01 · FY2018 · CA
An innate immune checkpoint in cancer immunotherapy$455,406
R01 · FY2017 · CA
Apical-basal polarity signaling in glioblastoma$301,150
R01 · FY2014 · CA · contact PI
Apical-basal polarity signaling in glioblastoma$67,717
R01 · FY2014 · CA · contact PI
Apical-basal polarity signaling in glioblastoma$1
R01 · FY2014 · CA · contact PI
Apical-basal polarity signaling in glioblastoma$291,837
R01 · FY2013 · CA · contact PI
Apical-basal polarity signaling in glioblastoma$65,622
R01 · FY2013 · CA · contact PI
Apical-basal polarity signaling in glioblastoma$310,465
R01 · FY2012 · CA · contact PI
Apical-basal polarity signaling in glioblastoma$54,631
R01 · FY2012 · CA · contact PI
Apical-basal polarity signaling in glioblastoma$310,465
R01 · FY2011 · CA · contact PI
Apical-basal polarity signaling in glioblastoma$332,942
R01 · FY2010 · CA · contact PI